Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,408.57
+29.852.17%
Number of Gainers:14
Number of Losers:4
Number of Flat:1
PE:- -
High:1,416.55
Open:1,393.57
Low:1,391.71
Close:1,378.72
Loading ...

Barclays Remains a Hold on Johnson & Johnson (JNJ)

TIPRANKS
·
2 hours ago

Is Johnson & Johnson a Good Dividend Stock to Buy Now?

Motley Fool
·
2 hours ago

Johnson & Johnson: Strong Performance Overshadowed by Biosimilar Competition and Litigation Risks

TIPRANKS
·
7 hours ago

Johanna Mercier, Chief Commercial Officer, Reports Disposal of Gilead Sciences Inc. Common Shares

Reuters
·
12 hours ago

Gilead Sciences CFO Andrew D. Dickinson Reports Disposal of Common Shares

Reuters
·
13 hours ago

Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025

GlobeNewswire
·
14 hours ago

US STOCKS-Wall Street ends higher after brief slump on Powell firing confusion

Reuters
·
14 hours ago

J&J Sees Lower Tariff Risk for the Year -- Market Talk

Dow Jones
·
18 hours ago

Pfizer’s Latest Clinical Study: A New Hope for Advanced Melanoma Treatment?

TIPRANKS
·
18 hours ago

Gilead Sciences Advances in Triple-Negative Breast Cancer Treatment

TIPRANKS
·
18 hours ago

Pfizer’s BeneFIX Study Completion: Market Implications and Insights

TIPRANKS
·
18 hours ago

J&J Exec Says Continue to Monitor What the Future Year's Impact Could Be From Tariffs on Our Business

THOMSON REUTERS
·
Yesterday

FDA: Discontinuation of Manufacture of Pfizer's Trecator, Tablet, 250 Mg - Website

THOMSON REUTERS
·
Yesterday

NanoViricides Inc. Announces Phase II Clinical Trial for NV-387 to Combat MPox Epidemic

Reuters
·
Yesterday

Abbott : Mizuho Raises Target Price to $140 From $130

THOMSON REUTERS
·
Yesterday

Astrazeneca's Anselamimab Misses Primary Goal in Phase III Amyloidosis Trial, Shares Down

MT Newswires Live
·
Yesterday

Johnson & Johnson Beats Sales Forecasts as Trump Renews Tariff Threats

Deep News
·
Yesterday

J&J Raises Full-Year Outlook After Beating 2Q Expectations

Dow Jones
·
Yesterday

BioNTech price target lowered to $126 from $127 at BofA

TIPRANKS
·
Yesterday

BioNTech SE (BNTX) Gets a Buy from Bank of America Securities

TIPRANKS
·
Yesterday